Chymopapain

Last updated
Chymopapain
1yal.jpg
Chymopapain's structure
Identifiers
EC no. 3.4.22.6
CAS no. 2593837
Databases
IntEnz IntEnz view
BRENDA BRENDA entry
ExPASy NiceZyme view
KEGG KEGG entry
MetaCyc metabolic pathway
PRIAM profile
PDB structures RCSB PDB PDBe PDBsum
Search
PMC articles
PubMed articles
NCBI proteins

Chymopapain (EC 3.4.22.6, chymopapain A, chymopapain B, chymopapain S, brand name Chymodiactin) is a proteolytic enzyme isolated from the latex of papaya (Carica papaya). It is a cysteine protease which belongs to the papain-like protease (PLCP) group. [1] Because of its proteolytic activity, it is the main molecule in the process of chemonucleolysis, used in some procedures like the treatment of herniated lower lumbar discs in the spine by a nonsurgical method. [2]

Contents

Structure

Primary structure

Chymopapain's zymogen is made up of a total of 352 residues, and it has a weight of approximately 23.78kDa. [3] Three different regions can be distinguished inside the precursor's chain. [3]

Image obtained using HotSpot Wizard 3.0 software by uploading chymopapain's PDB structure. A dimer of chymopapain can be observed. The highlighted orange regions represent the active site of each main chain. Chymopapain's quaternary structure.png
Image obtained using HotSpot Wizard 3.0 software by uploading chymopapain's PDB structure. A dimer of chymopapain can be observed. The highlighted orange regions represent the active site of each main chain.

Secondary and tertiary structures

Chymopapain's structure was solved by X-ray diffraction techniques. [3] Analysis of this structure showed chymopapain to have 7 alpha helix regions, 10 beta sheet regions and 2 loop turns. [3] These 2 turns are the main difference between chymopapain's structure and other papaya proteinase proteins such as papain or caricain, which have similar conformations. [11] [12]

Besides, chymopapain presents 3 disulfide bonds as post-traducional modifications stablished between residues 156–197, 190–229 and 287–338. [3]

Quaternary structure

Chymopapain presents a quaternary structure characterized by the formation of homo dimers, which means that two chymopapain chains join each other through weak interactions to conform one unique biological structure. [10]

Function

As well as all the other enzymes in the PLCPs group, chymopapain is a cysteine protease. Proteases are enzymes that hydrolyse peptide bonds between the residues that conform a protein. In every hydrolysis a water molecule is released. Specifically, a cysteine protease is an enzyme which breaks the peptide bond by using the thiol group of a cysteine residue as the nucleophile. In order to hydrolyse, the whole catalytic triad of the enzyme must be used. [1] This is constituted by a cysteine, the Cys159 residue, a histidine, the His203 residue, and a third residue, which tends to be an asparagine, specifically the Asn313 residue. [13] The functional groups used in the reaction are the thiol group of the cysteine and the imidazolium ring of a histidine. The asparagine residue works orientating the imidazolium ring of the histidine. [9]

Chymopapain hydrolysis mechanism step by step. Chymopapain hydrolysis mechanism..jpg
Chymopapain hydrolysis mechanism step by step.

The mechanism followed is exposed below: [9]

  1. The thiol group from the cysteine loses a proton, so it becomes negative charged and the amino group of the histidine catches a proton, which gives it a positive charge.
  2. The cysteine makes a bond with the carbon breaking the carbon's double bond with oxygen and converting it into a simple bond.
  3. The amino group is attracted by the positive charge of the histidine and a bond between these two is formed. The peptide bond is now broken and the carbonyl group is remade.
  4. The NH2R group is released from the histidine. The bond between the thiol group from the cysteine and the carbon is broken and a NHR group replaces it.

When this two bonds are broken, the catalytic triad from the chymopapain is available to be used again.

Synthesis

Chymopapain is no longer used as a standard method to treat chronic low back pain because of its potential side effects. [14] [15] Therefore, there is no need to synthesize it artificially. In fact, the sale and distribution of this protein was discontinued in the US in 2003.

Despite the huge amount of successful use to treat herniated disk disease, chymopapain use was discontinued not because of hazards or inadequacies but rather because it is no longer available due to a decision by its sole manufacturer to stop production. [16]

However, several studies have demonstrated different successful methods to extract and isolate the protease, which vary among authors. [17] [18] The most common procedure is the one described by Baines & Brocklehurst in 1979. [19]

In order to obtain the protein, Carica Papaya fruits are used, as chymopapain is found in its latex. The papayas should be just in the previous step before maturation, which implies an average diameter of 6–10 cm. [20]

Chymopapain extraction and isolation Chymopapain synthesis.png
Chymopapain extraction and isolation

Some longitudinal incisions of 2mm of depth have to be made through the skin to proceed to the extraction of latex, which can be collected in solid form some minutes after the extraction. The proteases present in the latex of the fruit are inactive precursors that are activated once the papaya is wounded. [21] In 0.3 ml of latex there are about 15 mg of chymopapain. [22]

If we want to conserve the proteolytic properties, latex has to be preserved with sodium metabisulfite and stored at a low temperature of about -10 °C. [23] If used immediately after the incisions, a buffer is added to extract the proteins: EDTA, ammonium sulfate or phosphate buffer all with a concentration of 0.5 mM and a pH of 7.

It is also important to block the thiol functions to avoid air oxidation and the loss of proteolytic activity. [21]

To eliminate organic and insoluble molecules, the sample is first filtered and afterwards centrifuged at 11000g for 30min. [22] The pellet is discarded and the supernatant added to 96% alcohol with a ratio of 1:3. [23] Impurities precipitate and can be eliminated by filtration. Afterwards, (NH4)2SO4 fractioning is done by addition of this substance at a concentration of 0.472 mg/ml. [22] Chymopapain precipitates and can be retrieved through another centrifugation, again at 11000g for 30min. The supernatant is discarded and the ion exchange chromatography can be carried out, with a linear gradient of 100mM (Na+) and different volumes of elution. Studying A280 chymopapain is found in the fraction of 750-1000 ml. [21]

Once chymopapain has been isolated, it can be crystallized through the gradual addition of sodium chloride at pH 2.0, which can take up to 4 days. [24]

Medical applications

Herniated nucleus pulposus of an intervertebral disc. Herniated nucleus.jpg
Herniated nucleus pulposus of an intervertebral disc.
Chymopapain
Clinical data
Routes of
administration
Injection into intervertebral disc
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
ChemSpider
  • none
UNII
ChEMBL
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Chymopapain is one of the substracts used in chemonucleolysis (a type of percutaneous discectomy). [25] This method was a new proposal to treat primary lumbar intervertebral disc disease using a nonsurgical method. As a matter of fact, the treatment consists on an injection of proteolytic enzymes to dissolve the herniated nucleus pulposus of the intervertebral discs. Purified chymopapain is the main component of the injection, composed basically of 20 mg in five millilitres. It is provided in vials containing 10.000 units of the lyophilized agent with 0.37 mg of disodium edetate, [26] 3.5 mg of cysteine hydrochloride monohydrate and 1.0 mg of bisulfide. All of them work as stabilisers and activators. Sodium hydroxide is in charge of adjusting the PH of the solution. Then, the injection is rehydrated with 5 milliliters of sterile water.

A surgeon injects the solution directly into the herniated disc on the spine to dissolve part of it and ease the pain. This process is under fluoroscopic control. Chymopapain is responsible for catalysis, both in vivo and in vitro, a rapid reduction in the viscosity and, as a consequence, the weight of the nucleus pulposus. In fact, it is a depolymerization of the chondromucoprotein [27] and a decrease in the ability of a disk to imbibe fluid. The dose for a single intervertebral disc is 2 to 4 nanokatals, with a maximum dose per patient of 8 nanokatals. Chymopapain injections are normally given under local, rather than general, anaesthesia.

This enzyme has been studied by universities departments around the world. [28] [29] [30] It was tested as much in animals as in humans and, very rarely, did it cause serious side effects including paralysis of the legs and death. [31] It could also cause anaphylaxis, but it was only seen in 1% of the patients who received the medication.

The sale and distribution of chymopapain was discontinued in the United States on January 27, 2003, after the company producing it decided to stop selling it worldwide. [31] [32]

See also

Related Research Articles

<span class="mw-page-title-main">Protease</span> Enzyme that cleaves other proteins into smaller peptides

A protease is an enzyme that catalyzes proteolysis, breaking down proteins into smaller polypeptides or single amino acids, and spurring the formation of new protein products. They do this by cleaving the peptide bonds within proteins by hydrolysis, a reaction where water breaks bonds. Proteases are involved in numerous biological pathways, including digestion of ingested proteins, protein catabolism, and cell signaling.

A metalloproteinase, or metalloprotease, is any protease enzyme whose catalytic mechanism involves a metal. An example is ADAM12 which plays a significant role in the fusion of muscle cells during embryo development, in a process known as myogenesis.

<span class="mw-page-title-main">Tosyl phenylalanyl chloromethyl ketone</span> Chemical compound

Tosyl phenylalanyl chloromethyl ketone (TPCK) is a protease inhibitor. Its structural formula is 1-chloro-3-tosylamido-4-phenyl-2-butanone.

<span class="mw-page-title-main">Papain</span> Widely used enzyme extracted from papayas

Papain, also known as papaya proteinase I, is a cysteine protease enzyme present in papaya and mountain papaya. It is the namesake member of the papain-like protease family.

<span class="mw-page-title-main">Mountain papaya</span> Species of plant

The mountain papaya also known as mountain pawpaw, papayuelo, chamburo, or simply "papaya" is a species of the genus Vasconcellea, native to the Andes of northwestern South America from Colombia south to central Chile, typically growing at altitudes of 1,500–3,000 metres (4,900–9,800 ft).

<span class="mw-page-title-main">Catalytic triad</span> Set of three coordinated amino acids

A catalytic triad is a set of three coordinated amino acids that can be found in the active site of some enzymes. Catalytic triads are most commonly found in hydrolase and transferase enzymes. An acid-base-nucleophile triad is a common motif for generating a nucleophilic residue for covalent catalysis. The residues form a charge-relay network to polarise and activate the nucleophile, which attacks the substrate, forming a covalent intermediate which is then hydrolysed to release the product and regenerate free enzyme. The nucleophile is most commonly a serine or cysteine amino acid, but occasionally threonine or even selenocysteine. The 3D structure of the enzyme brings together the triad residues in a precise orientation, even though they may be far apart in the sequence.

<span class="mw-page-title-main">Cysteine protease</span> Class of enzymes

Cysteine proteases, also known as thiol proteases, are hydrolase enzymes that degrade proteins. These proteases share a common catalytic mechanism that involves a nucleophilic cysteine thiol in a catalytic triad or dyad.

Neurophysins are carrier proteins which transport the hormones oxytocin and vasopressin to the posterior pituitary from the paraventricular and supraoptic nucleus of the hypothalamus, respectively. Inside the neurosecretory granules, the analogous neurophysin I and II form stabilizing complexes via covalent interactions. Stabilizing neurophysin-hormone complexes that are formed within neurosecretory granules located in the posterior pituitary gland aid in intra-axonal transport. During intra-axonal transport, the neurophysin's are believed to prevent the bound hormone from leaking into the cytoplasmic space and proteolytic digestion via enzymes. However, due to the low concentration of neurophysin in the blood, it is likely the protein-hormone complex dissociates, indicating the neurophysin does not aid in transporting the hormone through the circulatory system.

<span class="mw-page-title-main">Cystatin</span> Group of endogenous cysteine proteinase inhibitors

The cystatins are a family of cysteine protease inhibitors which share a sequence homology and a common tertiary structure of an alpha helix lying on top of an anti-parallel beta sheet. The family is subdivided as described below.

<span class="mw-page-title-main">Ficain</span>

Ficain also known as ficin, debricin, or higueroxyl delabarre is a proteolytic enzyme extracted from the latex sap from the stems, leaves, and unripe fruit of the American wild fig tree Ficus insipida.

<span class="mw-page-title-main">Actinidain</span> Class of enzymes

Actinidain is a type of cysteine protease enzyme found in fruits including kiwifruit, pineapple, mango, banana, figs, and papaya. This enzyme is part of the peptidase C1 family of papain-like proteases.

<span class="mw-page-title-main">USP20</span> Protein-coding gene in the species Homo sapiens

Ubiquitin carboxyl-terminal hydrolase 20 is an enzyme that in humans is encoded by the USP20 gene.

Proteases are in use, or have been proposed or tried, for a number of purposes related to medicine or surgery. Some preparations involving protease have undergone successful clinical trials and have regulatory authorization; and some further ones have shown apparently useful effects in experimental medical studies. Proteases have also been used by proponents of alternative therapies, or identified in materials of traditional or folk medicine. A serine protease of human origin, activated protein C, was produced in recombinant form and marketed as Drotrecogin alfa and licensed for intensive-care treatment of severe sepsis. It was voluntarily withdrawn by the manufacturer in 2011 after being shown to be ineffective.

Cathepsin X is an enzyme. This enzyme catalyses the following chemical reaction

<span class="mw-page-title-main">Oligopeptidase</span> Enzymes that cleaves peptides but not proteins

An Oligopeptidase is an enzyme that cleaves peptides but not proteins. This property is due to its structure: the active site of this enzyme is located at the end of a narrow cavity which can only be reached by peptides.

Glycyl endopeptidase is an enzyme. This enzyme catalyses the following chemical reaction

Caricain is an enzyme. This enzyme catalyses the following chemical reaction: Hydrolysis of proteins with broad specificity for peptide bonds, similar to those of papain and chymopapain

<span class="mw-page-title-main">Zingibain</span>

Zingibain, zingipain, or ginger protease is a cysteine protease enzyme found in ginger rhizomes. It catalyses the preferential cleavage of peptides with a proline residue at the P2 position. It has two distinct forms, ginger protease I (GP-I) and ginger protease II (GP-II).

<span class="mw-page-title-main">Asparagine endopeptidase</span> Class of enzymes

Asparagine endopeptidase is a proteolytic enzyme from C13 peptidase family which hydrolyses a peptide bond using the thiol group of a cysteine residue as a nucleophile. It is also known as asparaginyl endopeptidase, citvac, proteinase B, hemoglobinase, PRSC1 gene product or LGMN, vicilin peptidohydrolase and bean endopeptidase. In humans it is encoded by the LGMN gene.

<span class="mw-page-title-main">Papain-like protease</span>

Papain-like proteases are a large protein family of cysteine protease enzymes that share structural and enzymatic properties with the group's namesake member, papain. They are found in all domains of life. In animals, the group is often known as cysteine cathepsins or, in older literature, lysosomal peptidases. In the MEROPS protease enzyme classification system, papain-like proteases form Clan CA. Papain-like proteases share a common catalytic dyad active site featuring a cysteine amino acid residue that acts as a nucleophile.

References

  1. 1 2 3 4 "Peptidase C1A, papain C-terminal (IPR000668)". InterPro. EMBL-EBI. Retrieved 2018-10-11.
  2. "Chymopapain Injection". MedicineNet. Archived from the original on 2009-08-04. Retrieved 2009-07-21.
  3. 1 2 3 4 5 6 7 8 9 10 Maes D, Bouckaert J, Poortmans F, Wyns L, Looze Y (December 1996). "Structure of chymopapain at 1.7 A resolution". Biochemistry. 35 (50): 16292–16298. doi:10.1021/bi961491w. PMID   8973203.
  4. 1 2 "Conserved Protein Domain (CDD) Family: Peptidase_C1A". National Center for Biotechnology Information (NCBI), National Library of Medicine. U.S. National Institutes of Health. Retrieved 2018-10-11.
  5. Oberg KA, Ruysschaert JM, Azarkan M, Smolders N, Zerhouni S, Wintjens R, et al. (November 1998). "Papaya glutamine cyclase, a plant enzyme highly resistant to proteolysis, adopts an all-beta conformation". European Journal of Biochemistry. 258 (1): 214–222. doi: 10.1046/j.1432-1327.1998.2580214.x . PMID   9851712.
  6. Khan I, Polgar L (1983-11-08). "Purification and characterization of a novel proteinase, chymopapain S". Biochimica et Biophysica Acta (BBA) - General Subjects. 760 (3): 350–356. doi:10.1016/0304-4165(83)90372-0.
  7. "Chymopapain - Carica papaya (Papaya)". UniProt. Retrieved 2018-10-11.
  8. "SMART: Inhibitor_I29 domain annotation". Simple Modular Architecture Research Tool (SMART). Biobyte Solutions GmbH. Retrieved 2018-10-11.
  9. 1 2 3 López-Iglesias M, Gotor-Fernández V (August 2015). "Recent Advances in Biocatalytic Promiscuity: Hydrolase-Catalyzed Reactions for Nonconventional Transformations". Chemical Record. 15 (4): 743–759. doi:10.1002/tcr.201500008. hdl: 10651/34362 . PMID   26147872.
  10. 1 2 "HotSpot Wizard 3.0". loschmidt.chemi.muni.cz. Retrieved 2018-10-11.
  11. Jacquet A, Kleinschmidt T, Schnek AG, Looze Y, Braunitzer G (May 1989). "The thiol proteinases from the latex of Carica papaya L. III. The primary structure of chymopapain". Biological Chemistry Hoppe-Seyler. 370 (5): 425–434. doi:10.1515/bchm3.1989.370.1.425. PMID   2500950.
  12. Watson DC, Yaguchi M, Lynn KR (February 1990). "The amino acid sequence of chymopapain from Carica papaya". The Biochemical Journal. 266 (1): 75–81. doi:10.1042/bj2660075. PMC   1131098 . PMID   2106878.
  13. Gariev IA. "HCS: Chymopapain". www.enzyme.chem.msu.ru. Retrieved 2018-10-20.
  14. Deeb ZL, Schimel S, Daffner RH, Lupetin AR, Hryshko FG, Blakley JB (April 1985). "Intervertebral disk-space infection after chymopapain injection". AJR. American Journal of Roentgenology. 144 (4): 671–674. doi:10.2214/ajr.144.4.671. PMID   3156470. S2CID   18909656.
  15. Sussman BJ (April 1975). "Inadequacies and hazards of chymopapain injections as treatment for intervertebral disc disease". Journal of Neurosurgery. 42 (4): 389–396. doi:10.3171/jns.1975.42.4.0389. PMID   123576.
  16. Wardlaw D (2016). "Sciatica caused by disc herniation: Why is Chymopapain Chemonucleolysis denied to our patients?". International Journal of Spine Surgery. 10: 44. doi:10.14444/3044. PMC   5374990 . PMID   28377858.
  17. Monti R, Basilio CA, Trevisan HC, Contiero J (2000). "Purification of papain from fresh latex of Carica papaya". Brazilian Archives of Biology and Technology. 43 (5): 501–507. doi: 10.1590/S1516-89132000000500009 . hdl: 11449/20106 . ISSN   1516-8913.
  18. Buttle DJ, Barrett AJ (October 1984). "Chymopapain. Chromatographic purification and immunological characterization". The Biochemical Journal. 223 (1): 81–88. doi:10.1042/bj2230081. PMC   1144267 . PMID   6437389.
  19. Baines BS, Brocklehurst K (February 1979). "A necessary modification to the preparation of papain from any high-quality latex of Carica papaya and evidence for the structural integrity of the enzyme produced by traditional methods". The Biochemical Journal. 177 (2): 541–548. doi:10.1042/bj1770541. PMC   1186404 . PMID   435250.
  20. Aguirre E, Castillo P (2009-09-15). Extracción y estudio comparativo de las enzimas proteolíticas del fruto toronche (carica-stipulata) y de la papaya (carica-papaya) y su aplicación en la industria alimenticia (Report).
  21. 1 2 3 Azarkan M, El Moussaoui A, van Wuytswinkel D, Dehon G, Looze Y (June 2003). "Fractionation and purification of the enzymes stored in the latex of Carica papaya". Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences. 790 (1–2): 229–238. doi:10.1016/s0021-9673(02)01534-0. PMID   12767335.
  22. 1 2 3 Buttle DJ, Barrett AJ (October 1984). "Chymopapain. Chromatographic purification and immunological characterization". The Biochemical Journal. 223 (1): 81–88. doi:10.1042/bj2230081. PMC   1144267 . PMID   6437389.
  23. 1 2 Andrade-Mahecha MM, Morales-Rodriguez O, Martinez-Correa HA (2013). Study of the extraction process of papain from latex of papaya ( Carica papaya L . ) fruits cv . Maradol (PDF) (Report).
  24. Ebata M, Yasunobu KT (April 1962). "Chymopapain. I. Isolation, crystallization, and preliminary characterization". The Journal of Biological Chemistry. 237: 1086–1094. doi: 10.1016/S0021-9258(18)60289-3 . PMID   13888995.
  25. "Chemonucleolysis" (PDF). Couto JMC, Castilho EA de, Menezes PR. Chemonucleolysis in lumbar disc herniation: a meta-analysis. Clinics. 2007;62(2):175-80.
  26. "Edetate disodium". PubChem. U.S. National Library of Medicine.
  27. "Description of chondromucoprotein". The Free Dictionary.
  28. Ebata M, Yasunobu KT (April 1962). "Chymopapain. I. Isolation, crystallization, and preliminary characterization" (PDF). The Journal of Biological Chemistry. 237: 1086–94. doi: 10.1016/S0021-9258(18)60289-3 . PMID   13888995.
  29. Knezevic NN, Mandalia S, Raasch J, Knezevic I, Candido KD (May 2017). "Treatment of chronic low back pain - new approaches on the horizon". Journal of Pain Research. 10: 1111–1123. doi: 10.2147/jpr.s132769 . PMC   5436786 . PMID   28546769.
  30. Wardlaw D (2016). "Sciatica caused by disc herniation: Why is Chymopapain Chemonucleolysis denied to our patients?". International Journal of Spine Surgery. 10: 44. doi:10.14444/3044. PMC   5374990 . PMID   28377858.
  31. 1 2 "Chymopapain". The Mayo Clinic.
  32. "The Current Status of Chymopapain". Archived from the original on 2016-01-21. Retrieved 2013-04-01.

Further reading